Bio-Rad Laboratories Class A (BIO) closed at $369.00 on November 5, 2026, down 2.9% from the previous close, on volume of 416,177 shares (30-day average 224,820).
Data as of November 5, 2026.
RBC Capital Sticks to Their Buy Rating for Bio-Rad Laboratories (BIO)
TipRanks (Thu, 5-Nov 7:37 AM ET)
Bio-Rad Reports Third-Quarter Results and Improved Profitability
TipRanks (Wed, 4-Nov 5:43 PM ET)
Bio-Rad Laboratories, Inc. GAAP EPS of $2.65, revenue of $656.4M beats by $6.45M
Seeking Alpha News (Wed, 4-Nov 4:47 PM ET)
Bio-Rad Reports Third-Quarter 2026 Financial Results
Business Wire (Wed, 4-Nov 4:15 PM ET)
Bio-Rad Laboratories Q3 2026 Earnings Preview
Seeking Alpha News (Tue, 3-Nov 5:35 PM ET)
Bio-Rad to Participate in Fireside Chat During UBS Global Healthcare Conference
Business Wire (Thu, 29-Oct 4:30 PM ET)
Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026
Business Wire (Wed, 14-Oct 9:00 AM ET)
Business Wire (Wed, 16-Sep 9:00 AM ET)
Bio-Rad to Participate in Fireside Chat During Wells Fargo's 21st Annual Healthcare Conference
Business Wire (Mon, 31-Aug 9:00 AM ET)
IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
Globe Newswire (Mon, 10-Aug 4:05 PM ET)
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Bio-Rad Laboratories Class A trades on the NYSE stock market under the symbol BIO.
As of November 6, 2026, BIO stock price climbed to $381.25 with 130,914 million shares trading.
BIO has a beta of 1.01, meaning it tends to be more sensitive to market movements. BIO has a correlation of 0.10 to the broad based SPY ETF.
BIO has a market cap of $10.28 billion. This is considered a Large Cap stock.
Last quarter Bio-Rad Laboratories Class A reported $656 million in Revenue and $2.65 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.35.
In the last 3 years, BIO traded as high as $396.23 and as low as $211.43.
The top ETF exchange traded funds that BIO belongs to (by Net Assets): IJH, VTI, VB, DFSV, VBR.
BIO has outperformed the market in the last year with a price return of +23.0% while the SPY ETF gained +10.1%. BIO has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +9.6% and +4.9%, respectively, while the SPY returned -3.8% and -3.3%, respectively.
BIO support price is $361.00 and resistance is $377.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BIO shares will trade within this expected range on the day.
